UpadacitinibUPA45ulcerative colitisUPA305-ASAUPA15UPAU-ACCOMPLISH
…Introduction Upadacitinib (UPA) is an oral, selective, reversible janus kinase (JAK) 1 in…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 32 of 2459Upadacitinibulcerative colitisUPA30UPA15
…Introduction Upadacitinib (UPA), an oral, reversible Janus kinase inhibitor is approved f…
Terlipressinrespiratory failureUniversity Hospitals BirminghamMHRA
…ission (IQR 95–216) and 191 µmol/L at initiation (IQR 132–271). Terlipressin was bolus in 40/49 (81.6%) and continuous infusion in 9/49 (18.…
SScSkin fibrosisTGF-b1nintedanibBAG3
… action through BAG3 pathway inhibition (figure 1E).Conclusions SSc skin fibroblasts exhibit constitutive BAG3 overexpression coupl…
mycophenolate mofetiltofacitinibtocilizumabrituximabmethotrexateupadacitinibPeking Union Medical College Hospitalsystemic sclerosis (SSc)MTXUniversity of California, Los Angeles+1 more
…citinib or upadacitinib), rituximab, tocilizumab, methotrexate, mycophenolate mofetil, or glucocorticoids (>=10 mg prednisone equivalent daily) for m…
Antiphospholipid SyndromeSjogren’s syndromeSystemic Lupus ErythematosusUndifferentiated Connective Tissue DiseaseSjögren’s SyndromeRelapsing polychondritisEhlers-Danlos SyndromesIdiopathic Inflammatory MyopathiesSystemic lupus erymematosusIgG4-Related Diseases+2 more
…sue Disease (MCTD), Relapsing Polychondritis) and complex CTDs (Antiphospholipid Syndrome, Idiopathic Inflammatory Myopathies, Sjögren’s Syndrome, System…
Human PapillomavirusgonorrheaHIVHPVInfectious Diseases Day Hospital of PerugiaPerugia Infectious Diseases Day HospitalPrEPsyphilisChlamydiahepatitis A
…rotection against other sexually transmitted infections such as Human Papillomavirus (HPV); for this reason, it should be integrated into a multifac…
epididymo-orchitistesticular cancerTCUTI
…n 1964–1973 to 8.37 (7.99 to 8.77) in 2014–2018. Among men with epididymo-orchitis (n=89 596), TC was diagnosed in 0.45%, with an overall SIR of 6…
bronchiolitissalbutamol
…vidence for sustainability in de-implementing low-value care in bronchiolitis management.Trial registration details Australian and New Zealan…
91.5%
tumour-associated HLA-A*02 LOHBASECAMP-1TmodTempusDENALI-1Aware programmeTempus Aware programme
…r the BASECAMP-1 study; of these, 30 consented participants had tumour-associated HLA-A*02 LOH and met other study eligibility criteria. Using the Aware progr…
lymphomamultiple myelomaacute leukaemiaEQ-5DMMhaematologic malignancies
…moderate validity in AL (r=0.386, p=0.002) and poor validity in lymphoma (r=0.230, p=0.129). In patients with AL, chronic kidney failure…
baricitinibabrocitinibdupilumablebrikizumabtralokinumabupadacitinib
…numab 300 mg biweekly; and -44.15% (95% CI -50.44 to -37.86) vs baricitinib 2 mg diary. Statistically significant differences were found be…